Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Heres Why
Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
0,627€
4,77%
Echtzeit-Aktienkurs Verrica Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Verrica Pharmaceuticals Inc. Aktie
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%
The mean of analysts price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this…
Verrica Pharmaceuticals stock jumps after $50M financing deal By Investing.com
Verrica Pharmaceuticals stock jumps after $50M financing deal…
Lucid Capital Markets initiates Verrica Pharmaceuticals stock with Buy rating By Investing.com
Lucid Capital Markets initiates Verrica Pharmaceuticals stock with Buy rating…
Verrica Pharmaceuticals stock soars after Japan approves YCANTH By Investing.com
Verrica Pharmaceuticals stock soars after Japan approves YCANTH…
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 28.57% and 22.82%, respectively, for the quarter ended March 2025. Do…
Heres Why Verrica Pharmaceuticals (VRCA) Is a Great Buy the Bottom Stock Now
Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a…
Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript
…
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 4% and 80.78%, respectively, for the quarter ended December 2024. Do…
Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?
Verrica Pharmaceuticals (VRCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference
Oslo, Norway, January 22, 2025 – Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, has presented clinical data on Lytix lead drug…
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA),…
Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion
Oslo, November 21st 2024: Lytix Biopharma refers to the release made today by its licensing partner Verrica Pharmaceuticals, announcing the…
Verrica Announces Proposed Public Offering
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA),…
Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference
Oslo, Norway, October 24, 2024 - Lytix Biopharma, a Norwegian immuno-oncology company, today announces the acceptance of two abstracts showcasing…
Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript
…
PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy
Oslo, 14 August 2024. Lytix Biopharma (“Lytix”) announces that its Nasdaq-listed licensing partner Verrica Pharmaceuticals reports positive top-line Phase II…
Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14
Oslo, August 06, 2024. Lytix Biopharma announces that its licensing partner, Verrica Pharmaceuticals, will host an investor call to report…
Verrica Pharmaceuticals settles litigation with Dormer Labs By Investing.com
Verrica Pharmaceuticals settles litigation with Dormer Labs…
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones
Oslo, 30 May 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of…
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Earnings call: Verrica Pharmaceuticals reports on Q1 2024 performance By Investing.com
Earnings call: Verrica Pharmaceuticals reports on Q1 2024 performance…
Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript
…
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA),…
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
Verrica Pharmaceuticals (VRCA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Earnings call: Verrica Pharmaceuticals reports progress with YCANTH By Investing.com
Earnings call: Verrica Pharmaceuticals reports progress with YCANTH…